Similarly, Alanteet et al. showed that in models simulating obesity-associated breast cancer, liraglutide attenuated tumor cell proliferation by inhibiting the PI3K/Akt/mTOR signaling pathway [101]. Here, MTOR is linked to obesity due to melanocortin 4 receptor deficiency.